stock-detail (GSK)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia

6/14/2016 11:05 am

(Yahoo! Finance) June 14, 2016 - Celator Pharmaceuticals, Inc. today announced positive response rate results in AML patients with FLT3 (FMS-like tyrosine kinase-3) mutation were presented at the European Hematology Association (EHA) 21st Annual Congress. The results are from the Company's Phase 3 trial of VYXEOS™ (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML).

Experimental Liver Drug May Fight Cancer

5/20/2016 11:03 am

(San Diego Union-Tribune) May 19, 2016 - A drug in clinical trials for liver diseases by a San Diego biotech company may be useful in treating acute myeloid leukemia, according to research published this week.

ASCO Explains Its Opposition to Medicare Part B Demo During Key Congressional Hearing

5/18/2016 11:05 am

(ASCO in Action) May 17, 2016 - The oncology community voiced its strong opposition to the proposed Medicare Part B demonstration project today on Capitol Hill before the Health Subcommittee of the House Energy and Commerce Committee.

FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)

5/4/2016 07:00 am

(StreetInsider) May 3, 2016 - Acceptance reinforces significant unmet need for difficult-to-treat type of pediatric acute lymphoblastic leukemia.

CDC Confirms Zika Virus Causes Microcephaly, Other Birth Defects

4/14/2016 11:04 am

(Washington Post/To Your Health) Apr 13, 2016 - Federal health officials confirmed Wednesday that the Zika virus causes a rare birth defect and other severe fetal abnormalities, marking a turning point in an epidemic that has spread to more than 40 countries and territories in the Americas and elsewhere.

Internists, Specialists Lack Knowledge About FDA Drug Approval Process

4/12/2016 12:01 pm

(Medscape Medical News) Apr 12, 2016 - Most doctors do not fully understand the drug approval process for the US Food and Drug Administration (FDA) or the FDA's "breakthrough" drug classification, according to a survey published April 12 in JAMA.

Weird Loops Of Genetic Material Help Cause Cancer

4/1/2016 10:05 am

(Forbes) Mar 31, 2016 - Scientists have shown that an unusual form of genetic material can help cause blood cancers.

Déjà Vu for PTC as FDA Declines to Consider Duchenne Drug App

2/23/2016 01:01 pm

(Xconomy New York) Feb 23, 2016 - Two times, PTC Therapeutics has asked the FDA to look at an application to approve a Duchenne muscular dystrophy drug it’s been developing. And now two times, the agency has sent the South Plainfield, NJ-based company back to the drawing board.

Bristol-Myers Squibb Demonstrates Commitment to Hematology and Advancing Research and Development Across Multiple Blood Cancers Through Immuno-Oncology Leadership at the 20th Congress of the European Hematology Association

6/11/2015 11:03 am

(BMS) June 11, 2015 - Bristol-Myers Squibb will present data for elotuzumab, an investigational immunostimulatory antibody, in relapsed or refractory multiple myeloma; Opdivo (nivolumab), in patients with relapsed or refractory lymphoid malignancies; and Sprycel (dasatinib), in chronic myeloid leukemia.

Synta Announces Ganetespib Program Updates

6/2/2015 04:05 pm

(Synta) June 2, 2015 - Synta Pharmaceuticals Corp. today announced updates to its clinical program for Ganetespib, a next-generation inhibitor of the chaperone protein Hsp90.

Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease

5/31/2015 07:00 pm

(Benzinga) May 31, 2015 - Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA®) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

Imprime PGG-MAb Combination Therapy Achieves High Response Rate in Patients with Chronic Lymphocytic Leukemia

5/31/2015 07:00 pm

(MarketWatch) May 31, 2015 - A combination of Biothera’s Imprime PGG and the monoclonal antibodies alemtuzumab and rituximab achieved responses in 13 of 14 (93%) patients with high-risk chronic lymphocytic leukemia, including nine (64%) complete responses. Results of this phase 1/2 study will be presented today at the American Society of Clinical Oncology (ASCO).

Nivolumab Treatment in Melanoma Patients has Manageable Safety Profile, Additional Immunomodulatory Agents Do Not Affect Response Rates, Say Moffitt Cancer Center Researchers

5/29/2015 02:02 pm

(Moffitt) May 28, 2015 - The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients.

New Breast Cancer Screening Guidelines Explained

4/29/2015 11:05 am

(Washington Post) Apr 29, 2015 - Last week, my colleagues and I, as part of the U.S. Preventive Services Task Force, shared new draft recommendations on breast cancer screening. Our recommendations are based on an in-depth review of the strongest available science regarding mammography.

Vitamin Supplements Can Increase Risk of Cancer and Heart Disease

4/21/2015 11:04 am

(The Guardian [UK]) Apr 21, 2015 - Dietary supplements, such as over-the-counter multivitamins, do “more harm than good” and can increase the risk of developing cancer and heart disease, according to research in the US.

Researchers Find Protein That May Signal More Aggressive Prostate Cancers

4/13/2015 11:04 am

(University of Michigan) Apr 13, 2015 - University of Michigan researchers have discovered a biomarker that may be a potentially important breakthrough in diagnosing and treating prostate cancer.

Are Shortages Going Down or Not? Interpreting Data From the FDA and The University of Utah Drug Information Service

4/9/2015 12:03 pm

(Health Affairs blog) Apr 8, 2015 - Drug shortages are a significant public health issue that have affected many critically important drugs including chemotherapy treatments, nutritional support preparations, and antibiotics.

Statement from ASH President David A. Williams, MD, on Introduction of the Patients’ Access to Treatments Act in the House of Representatives

3/27/2015 11:02 am

(ASH) Mar 25, 2015 - Today Representatives David McKinley (R-WV) and Lois Capps (D-CA) introduced the Patients’ Access to Treatments Act in the House of Representatives, an important first step toward removing the burden of excessive cost-sharing for Americans who need high-cost, specialty-tier medications.

Congress Could Pursue a Permanent Medicare Physician Payment Fix

3/12/2015 12:01 pm

(California Healthline) Mar 12, 2015 - House and Senate leaders are discussing a permanent fix for Medicare's sustainable growth rate formula, lawmakers and aides said Wednesday, the Wall Street Journal reports (Peterson/Radnofsky, Wall Street Journal, 3/11).

New Survey Helps Doctors Better Assess Outcomes For Rectal Cancer Surgery

2/27/2015 12:00 pm

(MSKCC/OnCancer blog) Feb 26, 2015 - Surgery is the most common treatment for people with rectal cancer, but an operation is just the first step when it comes to restoring quality of life.

The Coming Wave of New Cancer Fighting Drugs

1/12/2015 11:03 am

(Bloomberg) Jan 10, 2015 - The hottest area in cancer drugs is going mainstream this year.

Sandoz Biosimilar Filgrastim Recommended for Approval by FDA Oncologic Drugs Advisory Committee

1/7/2015 03:02 pm

(Nasdaq) Jan 7, 2015 - Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its investigational biosimilar filgrastim in the US.

End of Cancer-Genome Project Prompts Rethink of Research Strategy

1/6/2015 11:04 am

(Scientific American/Nature magazine) Jan 5, 2015 - A mammoth US effort to genetically profile 10,000 tumours has officially come to an end.

Express Scripts Gives AbbVie Exclusive Hepatitis C Billing

12/22/2014 11:04 am

(CNBC) Dec 22, 2014 - Express Scripts says its largest plan will cover only AbbVie's hepatitis C regimen, excluding drugs from Gilead and J&J.

Novel Approach for Estrogen-receptor-positive Breast Cancer Reported

12/10/2014 03:03 pm

(Loyola Health Sciences) Dec 10, 2014 - Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.